Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BO-001
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Recipient : Biophta
Deal Size : $6.9 million
Deal Type : Financing
BIOPHTA Raises 6.5M Euros Funding to Transition its New Standard of Care for Eye Diseases
Details : The financing aims to fund the first-in-human trial of breakthrough topical ophthalmic investigational product BO-001 for the the treatment of glaucoma.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 06, 2024
Lead Product(s) : BO-001
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Recipient : Biophta
Deal Size : $6.9 million
Deal Type : Financing
Lead Product(s) : Undisclosed,Hyaluronic Acid
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Recipient : GelMEDIX
Deal Size : Undisclosed
Deal Type : Financing
Details : This investment supports development of the GelMEDIX platform, which enables the delivery of therapeutics from small molecules to cell and gene therapies. HTL will produce methacrylate hyaluronic acid, a key component for specific parameters across the G...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 03, 2022
Lead Product(s) : Undisclosed,Hyaluronic Acid
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Recipient : GelMEDIX
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Botulinum Toxin A
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Eirion Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : As part of the agreement, HTL will validate and operate botulinum manufacturing facility in US. Botulinum is the active ingredient in Eirion's lead product candidate ET-01, a topical neuromodulator being developed for Crow's Feet wrinkles and primary axi...
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
August 09, 2021
Lead Product(s) : Botulinum Toxin A
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Eirion Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
KEY PRODUCTS
Reset All
HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.
